New CEO task by Roche was to bring the stock price below $60, so Roche could consider an acquisition. It is getting there.
Even if Roche offers some premium, the investors would lose badly in comparison to the past valuation. The CEO has been busy on this, not on improving a quality of management team.
New layoff lists are being prepared. Make sure you know whether your name is on a list. Also check who can be influential in this process and who is responsible for singling you out.
Not certain about its identity. Collecting second or third grade managers from big pharma who settle on company dime in Tiburon for comfortable retirement.
